Manisha Bahl, MD, explained that ChatGPT and other large language models offer significant potential to help radiologists with breast imaging exams, but they are "not quite ready for primetime."
Evan Shlofmitz, DO, director of intravascular imaging at St. Francis Hospital, explains how advanced artificial intelligence technology is used to assess a patient's CT scan before they undergo PCI.
Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.
The newly approved PET radiotracer is expected to improve patient care significantly. “We have been able to reach the pinnacle of myocardial perfusion imaging with flurpiridaz," one expert said.
GE HealthCare's flurpiridaz, the PET radiotracer that recently received FDA approval, offers several key benefits over SPECT. Jamshid Maddahi, MD, discussed the details in an exclusive interview.
Digital breast tomosythesis now makes up close to 50% of mammography systems in the U.S. "Tomo is going to replace just straight digital mammography simply because of the benefit of fewer recalls," explained Debra L. Monticciolo, MD.
Debra L. Monticciolo, MD, past president of both the Society of Breast Imaging and the American College of Radiology, explains the advantages and disadvantages of current breast screening technology.
"A significant part of burnout stems from the overwhelming administrative burden," explains Elizabeth Ann Ignacio, MD, FSIR, FACR, chair of the SIR Small and Rural Practices Committee.
Dana Smetherman, MD, CEO of the American College of Radiology, explains resources available through its Data Science Institute to evaluate and validate the quality of imaging algorithms.
Clinicians have been using HeartSee to diagnose and treat coronary artery disease since the technology first debuted back in 2018. These latest updates, set to roll out to existing users, are designed to improve diagnostic performance and user access.
The cardiac technologies clinicians use for CVD evaluations have changed significantly in recent years, according to a new analysis of CMS data. While some modalities are on the rise, others are being utilized much less than ever before.
